

Aus dem Robert Koch-Institut, Berlin

**Are retroviruses  
involved in the etiopathogenesis of autoimmune diseases?**

**Development and application of test systems for the  
detection of retroviral gene expression**

Dissertation

zur Erlangung des akademischen Grades des  
Doktors der Naturwissenschaften (Dr. rer. nat.)

eingereicht im

Fachbereich Biologie, Chemie, Pharmazie der  
Freien Universität Berlin

vorgelegt von

Christine Uhlenhaut

aus Bad Gandersheim

August 2005



1. Gutachter: Prof. Dr. Georg Pauli

2. Gutachter: Prof. Dr. Volker Erdmann

Datum der Disputation: 13.1.2006

## Table of contents

	Table of contents .....	i
1	<b>Introduction</b> .....	1
1.1	Autoimmune diseases.....	1
1.1.1	Definition of autoimmune disease .....	1
1.1.2	Epidemiology of autoimmune diseases.....	2
1.1.3	Gender specific distribution of autoimmune diseases.....	3
1.1.4	Onset of autoimmune diseases .....	3
1.1.5	Etiology of autoimmune diseases.....	3
1.1.5.1	Genetic risk factors for autoimmune diseases.....	3
1.1.5.1.1	Genetic predisposition: familial risk factors for autoimmune diseases.....	4
1.1.5.1.2	Genetic predisposition: ethnic risk factors for autoimmune diseases .....	4
1.1.5.2	Environmental factors in autoimmune disease .....	5
1.1.5.3	Infectious agents in autoimmune disease .....	5
1.1.5.3.1	Retroviruses and autoimmune disease .....	5
1.1.6	Potential mechanisms for induction of autoimmunity .....	6
1.1.6.1	Molecular mimicry .....	6
1.1.6.2	Superantigens .....	6
1.1.6.3	Bystander activation.....	7
1.1.6.4	Activation of lymphocytes by lymphotropic viruses .....	7
1.1.6.5	Induction of autoimmune disease by endogenous retroviruses.....	7
1.2	Specific autoimmune diseases.....	7
1.2.1	Multiple sclerosis .....	7
1.2.1.1	Epidemiology of multiple sclerosis.....	8
1.2.1.1.1	Prevalence of multiple sclerosis.....	8
1.2.1.1.2	Gender related characteristics of multiple sclerosis.....	8
1.2.1.1.3	Onset of multiple sclerosis .....	9
1.2.1.2	Pathology of multiple sclerosis .....	9
1.2.1.3	Etiology of multiple sclerosis.....	10
1.2.1.3.1	Genetic susceptibility to multiple sclerosis.....	10
1.2.1.3.2	Ethnicity and multiple sclerosis .....	11
1.2.1.3.3	Environmental risk factors in multiple sclerosis.....	11
1.2.1.3.4	Infectious agents and multiple sclerosis.....	12
1.2.1.3.5	Vaccination and multiple sclerosis.....	12
1.2.1.4	Diagnosis/prognosis of multiple sclerosis.....	13
1.2.1.5	Treatment of multiple sclerosis.....	13
1.2.1.6	Animal models for multiple sclerosis .....	14
1.2.2	Scleroderma.....	14
1.2.2.1	Epidemiology of scleroderma .....	14
1.2.2.2	Pathology of scleroderma.....	15
1.2.2.3	Etiology of scleroderma .....	15
1.2.2.3.1	Genetic susceptibility to scleroderma .....	15
1.2.2.3.2	Ethnicity and scleroderma.....	16
1.2.2.3.3	Environmental risk factors in scleroderma .....	16
1.2.2.3.4	Infectious agents and scleroderma .....	16
1.2.2.4	Diagnosis/prognosis of scleroderma .....	16
1.2.2.5	Treatment of scleroderma .....	17
1.2.3	Systemic Lupus Erythematosus .....	17
1.2.3.1	Epidemiology of SLE.....	17
1.2.3.1.1	Gender related characteristics of SLE.....	18

Table of contents

1.2.3.1.2	Onset of SLE.....	18
1.2.3.2	Pathology of SLE.....	19
1.2.3.3	Etiology of SLE.....	19
1.2.3.3.1	Genetic susceptibility to SLE.....	19
1.2.3.3.2	Ethnicity and SLE.....	20
1.2.3.3.3	Environmental risk factors in SLE.....	20
1.2.3.3.4	Infectious agents and SLE.....	21
1.2.3.4	Diagnosis/prognosis of SLE.....	21
1.2.3.5	Treatment of SLE.....	21
1.2.3.6	Animal model for SLE.....	22
1.2.4	Spondylitis ankylosans.....	22
1.2.4.1	Epidemiology of spondylitis ankylosans.....	22
1.2.4.1.1	Gender related characteristics of spondylitis ankylosans.....	22
1.2.4.1.2	Onset of spondylitis ankylosans.....	23
1.2.4.2	Pathology of spondylitis ankylosans.....	23
1.2.4.3	Etiology of spondylitis ankylosans.....	23
1.2.4.3.1	Genetic susceptibility to spondylitis ankylosans.....	23
1.2.4.3.2	Ethnicity and spondylitis ankylosans.....	24
1.2.4.3.3	Infectious agents and spondylitis ankylosans.....	24
1.2.4.4	Diagnosis/prognosis of spondylitis ankylosans.....	24
1.2.4.5	Treatment of spondylitis ankylosans.....	25
1.3	Retroviruses.....	25
1.3.1	Retrovirus taxonomy.....	26
1.3.2	Host range.....	26
1.3.3	Morphology of retroviruses.....	27
1.3.4	Retrovirus genome.....	28
1.3.5	Replication cycle.....	30
1.3.6	Exogenous and endogenous retroviruses.....	31
1.3.6.1	Endogenous retroviruses.....	31
1.3.6.1.1	Origin of endogenous retroviruses.....	31
1.3.6.1.2	Classification of endogenous retroviruses.....	32
1.3.6.1.3	Distribution of endogenous sequences within the human genome.....	33
1.3.6.1.4	Biological implications of human endogenous retroviruses.....	33
1.3.6.1.4.1	Detrimental effects.....	34
1.3.6.1.4.2	Advantageous effects.....	34
1.3.6.1.5	Multiple sclerosis associated endogenous retroviruses.....	35
1.3.6.1.5.1	HERV-H/RGH.....	35
1.3.6.1.5.2	MSRV/HERV-W.....	35
1.3.6.1.6	Endogenous animal retroviruses.....	36
1.3.7	Exogenous human retroviruses.....	36
1.3.7.1	Human T cell lymphotropic virus (HTLV).....	36
1.3.7.1.1	Epidemiology of HTLV infections.....	37
1.3.7.1.2	Transmission of HTLV.....	37
1.3.7.1.3	Diagnosis of HTLV infection.....	37
1.3.7.1.4	Pathology of HTLV infections.....	37
1.3.7.1.5	Treatment of HTLV associated diseases.....	38
1.3.7.2	Human immunodeficiency virus HIV.....	38
1.3.7.2.1	Epidemiology of HIV infections.....	38
1.3.7.2.2	Classification of HIV.....	38
1.3.7.2.3	Transmission of HIV.....	39
1.3.7.2.4	Pathology of HIV infections.....	39
1.3.7.2.5	Diagnosis of HIV infection.....	39

1.3.7.2.6	Treatment of HIV infection.....	39
1.4	Aims .....	39
1.4.1	Samples .....	39
1.4.2	Generic approaches .....	40
1.4.3	Exogenous retroviruses – specific approach .....	40
1.4.4	Endogenous retroviruses – specific approach .....	41
2	<b>Material and methods</b> .....	42
2.1	Material .....	42
2.1.1	Expendable items .....	42
2.1.2	Chemicals .....	43
2.1.3	Kits .....	44
2.1.4	Nucleic acids, nucleotides, and markers .....	45
2.1.5	Enzymes and inhibitors .....	45
2.1.6	Buffers and solutions.....	45
2.1.6.1.1	Bacterial and cell culture media.....	45
2.1.6.1.1.1	Bacterial culture .....	45
2.1.6.1.1.2	Cell culture media .....	46
2.1.6.2	Solutions for cDNA synthesis and PCR.....	46
2.1.6.3	Solutions for gel electrophoresis .....	46
2.1.6.4	Other solutions and buffers .....	47
2.1.7	Laboratory apparatus.....	47
2.1.8	Software .....	49
2.2	Methods.....	49
2.2.1	Cell culture .....	49
2.2.1.1	General safety measures.....	49
2.2.1.2	Cultivation of cell lines .....	50
2.2.1.2.1	Adherent cell lines.....	50
2.2.1.2.2	Suspension cell lines .....	50
2.2.1.2.3	Employed cell lines .....	50
2.2.2	Isolation of nucleic acids.....	51
2.2.2.1	Quantification.....	51
2.2.2.2	DNA isolation .....	51
2.2.2.2.1	DNA isolation from whole blood.....	51
2.2.2.2.2	DNA isolation from PBMC .....	51
2.2.2.3	RNA isolation.....	52
2.2.2.3.1	Specific aspects for RNA .....	52
2.2.2.3.2	RNase-inhibitor .....	52
2.2.2.3.3	Total RNA isolation from cell culture .....	52
2.2.2.3.4	Total RNA isolation from virus pellets.....	52
2.2.2.3.5	Total RNA isolation from whole blood (EDTA/buffy coat).....	52
2.2.2.3.6	Total RNA isolation from whole blood (PAX-system) .....	52
2.2.2.3.7	Preparation of mRNA .....	53
2.2.3	Reverse transcriptase PCR (RT-PCR) .....	53
2.2.4	Polymerase chain reaction (PCR) .....	53
2.2.4.1	Specific PCR .....	54
2.2.4.2	Detection of PCR products – gel electrophoresis .....	54
2.2.4.3	Quantitative PCR – real-time PCR .....	55
2.2.4.3.1	TaqMan <sup>®</sup> protocol.....	55
2.2.4.3.1.1	Universal Master Mix .....	55
2.2.4.3.1.2	In house real-time mix .....	56
2.2.4.3.1.3	PCR profiles for real-time PCR .....	56
2.2.4.4	Analysis of TaqMan <sup>®</sup> data .....	57

2.2.4.5	Preventing contamination .....	57
2.2.5	Differential Display Reverse Transcriptase PCR (DDRT-PCR) .....	57
2.2.5.1	DDRT-PCR: cDNA-synthesis .....	58
2.2.5.2	Radio-labeling of PCR products .....	58
2.2.5.3	Denaturing polyacrylamide gel electrophoresis .....	59
2.2.5.4	Autoradiography .....	59
2.2.5.5	Selection of candidate bands and DNA elution .....	60
2.2.5.6	Re-amplification of PCR products .....	60
2.2.5.7	Purification of PCR products .....	60
2.2.6	Cloning .....	61
2.2.6.1	Cloning of PCR fragments .....	61
2.2.6.2	Transformation of competent cells .....	61
2.2.6.2.1	Preparation of competent bacteria .....	61
2.2.6.3	Colony PCR .....	61
2.2.6.4	Plasmid preparation .....	62
2.2.6.5	Plasmid standards for quantitative PCR .....	62
2.2.7	DNA Sequencing .....	63
2.2.7.1	Sequence reactions .....	63
2.2.7.2	Purification of sequencing reactions .....	63
2.2.7.3	Sequencing gel .....	63
2.2.7.4	Analysis of sequence data .....	64
2.2.8	Reverse Transcriptase Activity Assay (RTA) .....	64
2.2.8.1	Sample preparation .....	64
2.2.8.1.1	Preparation of cell culture supernatant .....	64
2.2.8.1.2	Preparation of plasma .....	64
2.2.8.2	Resuspension and lysis of the virus pellet, cDNA-synthesis .....	64
2.2.8.3	Quantification of reverse transcriptase activity .....	65
2.2.8.4	Antibody-stripping .....	66
2.2.8.5	Determination of viral load .....	67
2.2.9	Polyethylene glycol precipitation of virus particles .....	67
3	<b>Results</b> .....	68
3.1	Generic approaches .....	69
3.1.1	Differential display .....	69
3.1.2	Reverse transcriptase activity assay (RTA) .....	70
3.1.2.1	A catch all-method .....	70
3.1.2.2	Establishing optimized assay performance .....	71
3.1.2.2.1	Sample preparation .....	71
3.1.2.2.1.1	Filtration reduces RT activity in HIV-positive plasma .....	72
3.1.2.2.1.2	RT activity assay without antibody-stripping .....	73
3.1.2.2.1.3	RT activity assay including antibody-stripping .....	73
3.1.2.2.1.4	Comparison: filtration and sucrose cushion .....	74
3.1.2.2.2	Lysis of viral particles .....	75
3.1.2.2.3	Buffers .....	76
3.1.2.2.3.1	Buffer 1: cDNA buffers and bivalent cations .....	76
3.1.2.2.3.2	Buffer 2: cDNA buffers and BSA .....	77
3.1.2.2.3.3	Buffer 3: cDNA buffers and Tris concentration .....	77
3.1.2.2.3.4	Buffer 4: cDNA buffers and DTT-concentration .....	78
3.1.2.2.3.5	Buffer 5: storage buffer for enzyme standard dilution .....	79
3.1.2.2.4	Storage of samples .....	79
3.1.2.2.5	Assay range and internal control .....	80
3.1.2.2.6	Assay protection and background elimination .....	81
3.1.2.2.6.1	Influence of protease inhibitors .....	81

3.1.2.2.6.2	Lysate stability .....	82
3.1.2.2.6.3	RNase digestion of RNA template .....	82
3.1.2.2.6.4	Effects of RNase inhibitor RNasin.....	83
3.1.2.2.6.5	A DNA trap for background activity .....	84
3.1.2.2.6.6	Background of manganese buffer derived cDNA.....	85
3.1.2.2.7	Assay conditions .....	85
3.1.2.2.8	Assessment of the RTA assay performance.....	86
3.1.2.2.8.1	Standardization and quantification.....	86
3.1.2.2.8.2	Correlation of reverse transcriptase activity and viral load .....	86
3.1.2.2.8.3	Reproducibility.....	87
3.1.2.3	Analysis of RT activity in cell culture supernatants .....	88
3.1.2.3.1	RT activity in non-infected cell culture supernatant.....	89
3.1.2.3.2	RT activity in four different human melanoma cell lines .....	90
3.1.2.3.3	RT activity in a HERV-K mRNA expressing cell line .....	91
3.1.2.3.4	RT activity in Kasumi-1 cell culture supernatant .....	92
3.1.2.3.5	RT activity in porcine cell culture supernatant .....	93
3.1.2.3.6	Reverse transcriptase activity in two MS cell lines .....	94
3.1.2.3.6.1	Induction of virus growth.....	95
3.1.2.3.7	RT activity in cell culture supernatants infected with human retroviruses .....	96
3.1.2.3.7.1	RT activity in HIV-1 infected cell culture supernatant.....	96
3.1.2.3.7.1.1	Determination of viral load with the RTA compared to titration.....	96
3.1.2.3.7.1.2	Comparison of reverse transcriptase activity of drug-resistant and sensitive HIV.....	97
3.1.2.3.8	Results of the analysis of reverse transcriptase activity detected in cell culture supernatants.....	98
3.1.2.3.8.1	Comparison of reverse transcriptase activity in different cell lines.....	98
3.1.2.3.8.2	Determination of cation preference.....	99
3.1.2.4	Reverse transcriptase activity assay employing plasma samples.....	100
3.1.2.4.1	Detection of RT activity during HIV seroconversion .....	100
3.1.2.4.2	RT activity in plasma from autoimmune patients compared to healthy blood donors .....	102
3.1.2.4.2.1	Analysis of RT activity in healthy blood donors .....	102
3.1.2.4.2.2	RT activity in plasma from autoimmune disease patients .....	103
3.1.2.4.2.2.1	RT activity in plasma of spondylitis ankylosans patients .....	104
3.1.2.4.2.2.2	RT activity in plasma of SLE patients .....	104
3.1.2.4.2.3	RT activity in plasma of scleroderma patients.....	105
3.1.2.4.3	Results of the analysis of RT activity detected in plasma samples.....	106
3.2	Specific detection of expressed retroviral sequences.....	106
3.2.1	Expression of an exogenous retroviral sequence: HTLV .....	106
3.2.2	Expression of endogenous retroviral sequences .....	107
3.2.2.1	Standardization and quality assessment.....	108
3.2.2.2	Expression of HERV-H.....	110
3.2.2.3	Expression of MSRV .....	111
3.2.2.4	Expression of HERV-W.....	113
3.2.2.5	Gender specific differences in HERV sequence expression.....	114
3.2.2.6	Effect of therapy on HERV expression.....	117
3.2.2.7	Expression of endogenous sequences as diagnostic marker .....	118
3.2.2.7.1	Inter and intra assay variances for individual patients.....	119
3.2.2.7.2	Differences in expression of endogenous sequences for follow-up samples from therapy-naïve EOMS patients.....	119



3.2.2.7.3	Differences in expression of endogenous sequences for Rebif-treated individuals.....	121
3.2.2.7.3.1	Immediate reaction on Rebif therapy.....	121
3.2.2.7.3.2	Expression of endogenous sequences under long term treatment .....	121
3.2.2.7.4	Differences in expression of endogenous sequences for different states of MS.....	123
4	<b>Discussion</b> .....	125
4.1	Development of detection methods for retroviruses.....	126
4.2	Application of the specific test system .....	132
4.3	Investigations of MS cell lines and clinical samples .....	138
4.3.1	MS – cell lines .....	138
4.3.2	MS – clinical samples .....	140
4.4	Scleroderma .....	145
4.5	SLE .....	146
4.6	Spondylitis ankylosans.....	147
4.7	Perspectives.....	148
5	<b>Addendum</b> .....	152
5.1	Compilation of autoimmune diseases .....	152
5.2	Gender related distribution of selected AIDs.....	154
5.3	Age at onset of selected autoimmune diseases .....	154
5.4	Suggested viral associations for selected AIDs .....	154
5.5	Possible cross-reactive immune responses (molecular mimicry) .....	156
5.6	Retroviruses and associated diseases.....	156
5.7	Summary of mobile elements in the human genome.....	157
5.8	Endogenous and exogenous agents influencing the expression of HERVs .....	158
5.9	Global summary of the AIDS epidemic.....	158
5.10	HIV figures (worldwide).....	159
5.11	HIV/AIDS in Germany .....	159
5.12	Primers and probes.....	160
5.12.1	Primers and probes for housekeeping genes.....	160
5.12.2	Primers and probes for retrovirus specific quantitative PCR (exogenous sequences).....	160
5.12.3	Primers and probes for retrovirus specific quantitative PCR (endogenous sequences).....	161
5.12.4	Primers for DDRT-PCR.....	161
5.12.5	Primers and probes for reverse transcriptase activity assay.....	162
5.12.6	Primers for cloning .....	162
5.13	Compilation of tRNAs used as primers by reverse transcriptases.....	162
5.14	Table of figures .....	163
5.15	Tables.....	165
5.16	Abbreviations.....	166
5.16.1	Viruses .....	166
5.16.2	Miscellaneous abbreviations.....	168
6	<b>References</b> .....	173